Follow Us on Social:


liver cancer

Liver Cancer


Publications by J Hsiang

1. Danesh-Meyer HV, Carroll SC, Ku JY, Hsiang JC, Gaskin B, Gamble GD, Savino PJ. Correlat ion of retinal nerve fiber layer measured by scanning laser polarimeter to visual field in ischemic optic neuropathy. Ophthalmology. 2006 Apr;113(4):603-11

2. Danesh-Meyer HV, Ku JY, Papchenko TL, Jayasundera T, Hsiang JC, Gamble GD. Regional Correlation of structure and function in glaucoma, using the Disc Damage Likelihood Scale, Heidelberg Retinal Tomograph, and visual fields. Ophthalmology Ophthalmology. 2006 Apr;113(4):603-11

3. Hsiang JC, Bai W, Lal D. Symptom presentations and other characteristics of colorectal cancer patients and the diagnostic performance of the Auckland Regional Grading Criteria for Suspected Colorectal Cancer in the South Auckland population. N Z Med J 2013;126:95-107.

4. Hsiang JC, Selvaratnam S, Taylor S, et al. Increasing primary antibiotic resistance and ethnic differences in eradication rates of Helicobacter pylori infection in New Zealand–a new look at an old enemy. N Z Med J 2013;126:64-76.

5. Selvaratnam S, Yeoh J, Hsiang JC, Patrick AB. A win for the patient: Direct patient notification improves treatment rates of active Helicobacter pylori infection. The Australasian medical journal. 2014;7(8):350-4.

6. Hsiang JC, Wong GL, Chan HL, Chan AW, Chim AM, Wong VW. Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. Aliment Pharmacol Ther. 2014 Sep;40(6):716-26.

7. Hsiang JC, Bai WW, Raos Z, et al: Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand. Intern Med J 2015; 45:160-9

8. Hsiang JC, Gane EJ, Bai WW, et al: Type 2 diabetes: A risk factor for liver mortality and complications in hepatitis B cirrhosis patients. J Gastroenterol Hepatol 30:591-9, 2015

9. Hsiang JC, Wong, GL, Tse YK, et al: Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. J Hepatol 2015;63:1190-7.

10. Khoo J, Hsiang JC, Taneja R, Law N-M and Ang T-L. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial. Diabetes Obes Metab. 2017;19:1814–1817.

11. Wong YJ, Cheen MH, Hsiang JC, Kumar R, Tan J, Teo EK, Thurairajah PH. Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore. JGH Open. 2019 Feb 8;3(3):210-216. doi: 10.1002/jgh3.12139. PubMed PMID: 31276038;

12. Chan FKL, Kyaw MH, Hsiang JC, Suen BY, Kee KM, Tse YK, Ching JYL, Cheong PK, Ng D, Lam K, Lo A, Lee V, Ng SC. Risk of Postpolypectomy Bleeding With Uninterrupted
Clopidogrel Therapy in an Industry-Independent, Double-Blind, Randomized Trial. Gastroenterology. 2019 Mar;156 (4):918-925.e1. doi: 10.1053/j.gastro.2018.10.036. PubMed PMID: 30518511.

13. Tey TT, Maung AC, Lim KW, Hsiang JC. Acute Pancreatitis Caused by Tamoxifen-Induced Severe Hypertriglyceridemia After 4 Years of Tamoxifen Use. ACG Case Rep J. 2019 Feb;6(2):1-3. doi: 10.14309/crj.0000000000000025. PubMed PMID: 31157284;

14. Zhao Y, Thurairajah PH, Kumar R, Tan J, Teo EK, Hsiang JC. Novel non-invasive score to predict cirrhosis in the era of hepatitis C elimination: A population study of ex-substance users in Singapore. Hepatobiliary Pancreat Dis Int. 2019 Apr;18(2):143-148. doi: 10.1016/j.hbpd.2018.12.002. PubMed PMID: 30558838.

15. Koo SH, Chu CW, Khoo JJC, Cheong M, Soon GH, Ho EXP, Law NM, De Sessions PF, Fock KM, Ang TL, Lee EJD, Hsiang JC. A pilot study to examine the association between human gut microbiota and the host’s central obesity. JGH Open. 2019 Apr 16;3(6):480-487. doi:10.1002/jgh3.12184. PubMed PMID: 31832548;

16. Khoo J, Hsiang JC, Taneja R, Koo SH, Soon GH, Kam CJ, Law NM, Ang TL. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver Int. 2019 May;39(5):941-949. doi: 10.1111/liv.14065.

17. Wong YJ, Chew SY, Hsiang JC, Thurairajah PH, Kumar R, Teo EK, Gokhale RS, Noor IBM, Tan J. VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature. Clin Mol Hepatol. 2019 Jun;25(2):218-222. doi:10.3350/cmh.2018.0017.

18. Kumar R, Hsiang JC, Tan J, Thurairajah PH. Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of antidiuretic hormone: A case report. Clin Mol Hepatol. 2019 Sep;25(3):326-330. doi:10.3350/cmh.2018.0063. PubMed PMID: 30509013;

19. De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol. 2019 Sep 7;25(33):4933-4944. doi:10.3748/wjg.v25.i33.4933. PubMed PMID: 31543684

20. Koo SH, Deng J, Ang DSW, Hsiang JC, Lee LS, Aazmi S, Mohamed EHM, Yang H, Yap SY, Teh LK, Salleh MZ, Lee EJD, Ang TL. Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore. Singapore Med J. 2019 Oct;60(10):512-521. doi: 10.11622/smedj.2018152 PubMed PMID: 304880796 | P a g e C u r r i c u l u m V i t a e o f J o h n C h e n H S I A N G

21. Shah ND, Ventura-Cots M, Abraldes JG, Alboraie M, Alfadhli A, Argemi J, Badia-Aranda E, Arús-Soler E, Barritt AS 4th, Bessone F, Biryukova M, Carrilho FJ, Fernández MC, Dorta GuiridiZ, El Kassas M, Eng-Kiong T, Queiroz Farias A, George J, Gui W, Thurairajah PH, Hsiang JC, Husić-Selimovic A, Isakov V, Karoney M, Kim W, Kluwe J, Kochhar R, Dhaka N, Costa PM, Nabeshima Pharm MA, Ono SK, Reis D, Rodil A, Domech CR, Sáez-Royuela F, Scheurich C, Siow W, Sivac-Burina N, Dos Santos Traquino ES, Some F, Spreckic S, Tan S, Vorobioff J, Wandera A, Wu P, Yacoub M, Yang L, Yu Y, Zahiragic N, Zhang C, Cortez-Pinto H, Bataller R. Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. Clin Gastroenterol Hepatol. 2019 Oct;17(11):2320-2329.e12. doi:10.1016/j.cgh.2019.01.026. PubMed PMID: 30708110

22. Chaillon A, Thurairajah PH, Hsiang JC, Martin NK. What is required for achieving hepatitis C virus elimination in Singapore? A modeling study. J Gastroenterol Hepatol. 2020 Aug 10. doi:10.1111/jgh.15211. Epub ahead of print. PMID: 32777859.

23. Hsiang JC, Sinnaswami P, Lee MY, Zhang MM, Quek KE, Tan KH, Wong YM, Thurairajah PH. Point-of-care hepatitis C screening with direct access referral to improve linkage of care among people with substance misuse: a pilot randomised study. Singapore Med J. 2020 Jul 30. doi:10.11622/smedj.2020116. Epub ahead of print. PMID: 32729280.

24. Hsiang JC, Wong VW. SGLT2 Inhibitors in Liver Patients. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2168-2172.e2. doi: 10.1016/j.cgh.2020.05.021. Epub 2020 May 16. PMID: 32428710.